Bernstein raises Marriott stock price target on capex reimbursement By Investing.com

Bernstein raised Marriott International’s price target to $400 from $393 and lifted its 2026-2030 EPS CAGR estimate to more than 15% from 13%. The firm also sees 2026 net capex of about $700 million to $750 million after expected reimbursements, with net capex potentially falling below $500 million by 2029. Despite concerns over elevated capex versus peers, Marriott’s 79% gross margin, strong credit-card fee contribution and ongoing expansion support a constructive outlook.

Analysis

This is not a simple multiple re-rating story; it is a capital-allocation inflection. If the reimbursement math is right, Marriott’s near-term headline capex looks inflationary but the economic burden is materially lower, which means consensus has been overstating the drag on free cash flow and understating terminal margin durability. The market is still pricing MAR like a mature asset-light operator with modest reinvestment needs, but the next 12-24 months should look more like a temporary FCF compression phase followed by a step-up in cash conversion as reimbursements roll through.

The second-order beneficiary is Marriott itself versus Hilton and IHG on growth runway: higher digital spend can widen the moat if it improves direct booking mix, loyalty engagement, and owner economics faster than peers can replicate. That said, the spend also raises execution risk because technology transformation in hotels often front-loads cost and back-loads benefit; if adoption lags, the stock could de-rate on margin fear before the reimbursement narrative becomes visible in reported cash flow. Watch for any sign that owners resist pass-through economics or that incremental tech spend cannibalizes refurb/brand investment.

The clearest market inefficiency is that sell-side may still be anchoring on EBITDA while missing the timing mismatch between capex, reimbursement, and cash return. That creates an opportunity for a tactical long in MAR versus a peer basket, because the upside in EPS can be realized before the market fully capitalizes the lower net capex trajectory. The contrarian risk is that the stock is already near peak optimism and the incremental good news may be insufficient to offset valuation; if management misses on reimbursement timing by even one reporting cycle, the multiple could compress quickly.

Key Decisions for Investors

• Long MAR vs. IHG pair trade over 6-12 months: MAR should benefit more from the reimbursement-driven FCF inflection, while IHG lacks a similar near-term cash conversion catalyst; target 8-12% relative outperformance, stop if MAR loses credibility on capex reimbursement timing.
• Buy MAR on any 3-5% pullback following earnings/guidance updates: risk/reward improves once the market digests that reported capex is not the right economic denominator; expect multiple support if 2026 cash flow guidance tightens.
• Use MAR call spreads for a 6-9 month expression: upside is tied to re-rating on better-than-expected FCF, while downside is limited by already-high expectations; structure preferred over outright stock given valuation risk.
• Fade the peers most exposed to capital-light vs capital-heavy comparison risk with a small short basket in IHG and selective hotel-adjacent operators if MAR rerates first; the relative story matters more than sector direction.
• Set a trailing profit target on MAR after any 10-15% rally from current levels: once the reimbursement story is fully accepted, the next leg will depend on execution, not narrative, and the stock can stall near consensus price-target clustering.